Related Experiment Video
Updated: Aug 8, 2026
11:11
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Choline kinase: an important target for cancer
S Janardhan1, P Srivani, G Narahari Sastry
1Molecular Modeling Group, Organic Chemical Sciences, Indian Institute of Chemical Technology, Tarnaka, Hyderabad 0500 007, India.
Current Medicinal Chemistry
|May 25, 2006
Summary
Choline kinase (ChoK) is crucial for cell growth and phospholipid synthesis. Targeting ChoK and its role in cancer, particularly via RNA interference (RNAi), offers promising therapeutic strategies for various malignancies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Choline kinase (ChoK) catalyzes choline phosphorylation to phosphorylcholine (PCho), essential for cell membrane phospholipids and division.
- ChoK and PCho are implicated in malignant transformation via ras oncogenes in diverse cancers.
- ChoK activation involves Ras effectors like Raf-1, Ral-GDS, and PI3K during tumorigenesis.
Purpose of the Study:
- To provide a comprehensive overview of Choline kinase (ChoK).
- To review ChoK's importance, expression, structure, and role in carcinogenesis.
- To highlight progress in molecular modeling, active site analysis, and inhibitors of ChoK.
Main Methods:
- Literature review focusing on Choline kinase (ChoK) function and cancer relevance.
- Analysis of ChoK's involvement in Ras-dependent and independent carcinogenesis.
- Exploration of RNA interference (RNAi) as a cancer therapeutic strategy targeting ChoK.
Main Results:
- ChoK plays a vital role in cell signaling, growth regulation, and phospholipid synthesis.
- ChoK gene induction is linked to cellular stress and defense mechanisms.
- RNAi-mediated suppression of oncogenic ras demonstrates anticancer potential in various cancer models.
Conclusions:
- ChoK is a significant target in cancer therapy due to its role in tumorigenesis.
- Molecular modeling and structural analysis of ChoK can aid in inhibitor design.
- RNAi represents a promising approach for sequence-specific gene silencing in cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: